News

Grenova Secures New Investment; Appoints Life Sciences Veteran to the Board

Grenova, Inc., a Virginia-based innovator in sustainable laboratory technologies, today announced two significant milestones for the company: the appointment of Ted Hull to Grenova’s board, and the successful completion of a new round of growth equity capital. These developments support Grenova’s strategic vision to drive innovation, expand automation capabilities, and deliver transformative solutions to laboratories worldwide. 

Ted Hull brings over 30 years of experience in the life sciences industry, including as a clinical lab CEO for the last 20+ years. In his role at Grenova, Mr. Hull is set to provide strategic leadership and to play a pivotal role in shaping the company’s future. 

“I am honored to join Grenova at such an exciting time in the company’s journey,” said Hull. “Grenova is revolutionizing the way laboratories think about and use plastics—transforming single-use mindsets into sustainable, reusable solutions. I look forward to working closely with this talented team to continue driving meaningful change.” 

The addition to Grenova’s team is complemented by a new round of equity capital. The funding will be used to enhance Grenova’s automation portfolio, expand R&D capabilities, and grow the team to meet rising demand across global markets. The financing was led by Grenova investors, Peloton Equity and Hamilton Lane’s (Nasdaq: HLNE) Impact Fund II, along with other existing investors,  

“This investment affirms confidence in our vision and the market’s urgency to reduce plastic waste,” said Katherine Marrs, CEO of Grenova. “With this capital and Ted Hull on the board, we’re positioned to accelerate our mission to scale sustainable lab practices.” 

“We are excited to continue supporting Grenova’s growth,” said Ted Lundberg, Peloton Equity Managing Partner and Grenova’s Chairman. “We have worked with Ted Hull over the past 20 years and are thrilled to have him join Grenova. Ted brings a powerful blend of vision and experience that will help Grenova press its advantage as a category leader.” 

Backed by experienced leadership, a unique and patent protected product suite, strong investor confidence, and a clear vision, Grenova is working revolutionize laboratories worldwide. 

 

Read more here.

Recent News

10/23/2026

PAK BioSolutions and iBET Advance Integrated Continuous AAV8 Purification

PAK BioSolutions today announced the publication of a peer-reviewed study on integrated, continuous purification of adeno-associated virus serotype 8 (AAV8) using the PAK PD™ Process Development Scale Continuous Purification System. Conducted in collaboration with iBET – Instituto de Biologia Experimental e Tecnológica, the study, “Streamlining AAV8 Purification with Cyclic Integrated Capture–Polishing Chromatography,” was published in …

10/22/2026

Lilly breaks ground in Richmond to expand American manufacturing of next-generation cancer medicines, advancing its build-out of 10 new U.S. sites since 2020

Eli Lilly and Company (NYSE: LLY) broke ground today on a new $5 billion manufacturing facility just west of Richmond, Virginia, in Goochland County, one of 10 new U.S. manufacturing sites announced since 2020 and one of five among them that will produce active pharmaceutical ingredients (API). As part of the company’s more than $50 …

10/21/2026

United Therapeutics Expands Organ Manufacturing Capabilities with Opening of Third Designated Pathogen-Free Xenograft Production Facility

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the opening of its third Designated Pathogen-Free (DPF) facility, The Dr. Bartley P. Griffith and Dr. Robert A. Montgomery Xenograft Production Facility, in Houston, Texas. United Therapeutics opened its first DPF facility in Christiansburg, Va. in 2024 to produce xenografts for ongoing clinical trials. …